| 產(chǎn)品編號 | bs-5534R-BF350 |
| 英文名稱1 | Rabbit Anti-Phospho-PDGFRA(Tyr762)/BF350 Conjugated antibody |
| 中文名稱 | BF350標(biāo)記的磷酸化血小板源性生長因子受體α |
| 別 名 | PDGFRA(phospho Y762); PDGF Receptor alpha(Tyr849)/PDGF Receptor beta (Tyr857); Platelet–dirived growth factor receptor-alpha; Alpha platelet derived growth factor receptor; CD 140a; CD140a; CD140a antigen; MGC74795; PDGF alpha chain; PDGF R alpha; PDGFR 2; PDGFR A; PDGFR alpha; PDGFR2; PDGFRA; Platelet derived growth factor receptor 2; Platelet derived growth factor receptor alpha; Platelet derived growth factor receptor alpha polypeptide; PGFRA_HUMAN. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 產(chǎn)品類型 | 磷酸化抗體 |
| 研究領(lǐng)域 | 腫瘤 免疫學(xué) 信號轉(zhuǎn)導(dǎo) 轉(zhuǎn)錄調(diào)節(jié)因子 激酶和磷酸酶 細(xì)胞膜受體 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human, Mouse, Rat, Dog, ) |
| 產(chǎn)品應(yīng)用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 117kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated Synthesised phosphopeptide derived from human PDGFRA around the phosphorylation site of Tyr762 [SL(p-Y)DR] |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: The PDGF Receptor Type A (Alpha platelet-derived growth factor receptor precursor, CD140a antigen), a 170kD protein, binds all three isoforms of PDGF with high affinity whereas the PDGF Receptor Type B, a 190kD protein, appears to bind only the PDGF BB homodimer with high affinity. Both receptors are transmembranous, ligand activated protein tyrosine kinases, which phosphorylate a number of important signal transduction proteins, which are bound with differential affinities via SH2 domains. The response of any given cell to PDGF will depend on the types of receptors displayed on the surface and isoforms of PDGF present in the extracellular environment. Function: Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for normal skeleton development and cephalic closure during embryonic development. Required for normal development of the mucosa lining the gastrointestinal tract, and for recruitment of mesenchymal cells and normal development of intestinal villi. Plays a role in cell migration and chemotaxis in wound healing. Plays a role in platelet activation, secretion of agonists from platelet granules, and in thrombin-induced platelet aggregation. Binding of its cognate ligands - homodimeric PDGFA, homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFC -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PIK3R1, PLCG1, and PTPN11. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylates PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and thereby mediates activation of the AKT1 signaling pathway. Mediates activation of HRAS and of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3 and STAT5A and/or STAT5B. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor. Subunit: Interacts with homodimeric PDGFA, PDGFB and PDGFC, and with heterodimers formed by PDGFA and PDGFB. Monomer in the absence of bound ligand. Interaction with dimeric PDGFA, PDGFB and/or PDGFC leads to receptor dimerization, where both PDGFRA homodimers and heterodimers with PDGFRB are observed. Interacts (tyrosine phosphorylated) with SHB (via SH2 domain). Interacts (tyrosine phosphorylated) with SHF (via SH2 domain). Interacts (tyrosine phosphorylated) with SRC (via SH2 domain). Interacts (tyrosine phosphorylated) with PIK3R1. Interacts (tyrosine phosphorylated) with PLCG1 (via SH2 domain). Interacts (tyrosine phosphorylated) with CRK, GRB2 and GRB7. Interacts with human cytomegalovirus/HHV-5 envelop glycoprotein B/gB. Subcellular Location: Cell membrane; Single-pass type I membrane protein. Note=The activated receptor is rapidly internalized and degraded. Tissue Specificity: Detected in platelets (at protein level). Widely expressed. Detected in brain, fibroblasts, smooth muscle, heart, and embryo. Expressed in primary and metastatic colon tumors and in normal colon tissue. Post-translational modifications: N-glycosylated. Ubiquitinated, leading to its degradation (Probable). Autophosphorylated on tyrosine residues upon ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Phosphorylation at Tyr-731 and Tyr-742 is important for interaction with PIK3R1. Phosphorylation at Tyr-720 and Tyr-754 is important for interaction with PTPN11. Phosphorylation at Tyr-762 is important for interaction with CRK. Phosphorylation at Tyr-572 and Tyr-574 is important for interaction with SRC and SRC family members. Phosphorylation at Tyr-988 and Tyr-1018 is important for interaction with PLCG1. DISEASE: Note=A chromosomal aberration involving PDGFRA is found in some cases of hypereosinophilic syndrome. Interstitial chromosomal deletion del(4)(q12q12) causes the fusion of FIP1L1 and PDGFRA (FIP1L1-PDGFRA). Mutations that cause overexpression and/or constitutive activation of PDGFRA may be a cause of hypereosinophilic syndrome. Defects in PDGFRA are a cause of gastrointestinal stromal tumor (GIST) [MIM:606764]. Note=Mutations that cause constitutive activation of PDGFRA may be a cause of gastrointestinal stromal tumor (GIST). Similarity: Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily. Contains 5 Ig-like C2-type (immunoglobulin-like) domains. Contains 1 protein kinase domain. Database links: Entrez Gene: 5156 Human Entrez Gene: 18595 Mouse Omim: 173490 Human SwissProt: P16234 Human SwissProt: P26618 Mouse Unigene: 74615 Human Unigene: 221403 Mouse Unigene: 55127 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. PDGFR-α是膜受體，具有酪氨酸酶的活性，與其配體PDGF結(jié)合后激活與細(xì)胞增殖有關(guān)的酶及基因。 PDGFR亦表達(dá)于上皮、內(nèi)皮細(xì)胞，前列腺、皮膚、腎小球等上皮細(xì)胞均有PDGFR表達(dá). 亦有學(xué)者報道血小板源性生長因子受體α抗體在細(xì)胞胞漿胞膜、胞核都有不同的表達(dá)還有人認(rèn)為：PDGF及其受體一般表達(dá)于浸潤病變組織的炎癥細(xì)胞附近，組織缺血損傷、腎小球高壓、免疫因素作用、炎癥細(xì)胞浸潤、實質(zhì)細(xì)胞活化等導(dǎo)致PDGFR表達(dá)增強(qiáng)。 |
